PTCY-Based Haploidentical Donor Transplantation versus HLA-Matched Related and Unrelated Donor Transplantations in Patients with Refractory or Relapsed Lymphoma—A Matched-Pair Analysis
Cancers · 31.10.2023 · 15 (21) · 5246
DOI: 10.3390/cancers15215246 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 31.10.2023. Verfasst von Sarah Haebe und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine III, Ludwig-Maximilians-University (LMU) University Hospital Munich, 81377 Munich, Germany. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has demonstrated its potential as a curative option for patients with r/r lymphoma. With the introduction of post-transplant cyclophosphamide-based (PTCY) graft-versus-host disease (GvHD) prophylaxis, allo-HCT using haploidentical related donors (Haplo-HSCT) has emerged as a valuable alternative for patients without an available HLA-matched donor. In this study, we compared intermediate and long-term outcomes between Haplo-HSCT and HLA-matched related donor (MRD) and unrelated donor (URD) transplantations in 16 matched pairs using age, disease status, lymphoma classification and performance status as matching criteria. Of note, 88% of patients in each group presented with active disease at the time of conditioning. After a median follow-up of >10 years, 10-year overall and progression-free survival and non-relapse mortality incidence after Haplo-HSCT were 31%, 25% and 38%, respectively, and did not differ compared to the values observed in MRD-HSCT and URD-HSCT. A remarkable lower incidence of acute GvHD ≥ II and moderate and severe chronic GvHD was observed after Haplo-HSCT compared to MRD-HSCT (50%/50%, p = 0.03/0.03) and URD-HSCT (44%/38%, p = 0.04/0.08), resulting in slightly higher 10-year GvHD-free and relapse-free survival (25%) and chronic GvHD-free and relapse-free survival (25%) in the Haplo-HSCT group. In conclusion, Haplo-HSCT is an effective treatment in patients with non-remission NHL. Given its advantage of immediate availability, haploidentical donors should be preferably used in patients with progressive disease lacking an HLA-matched related donor.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine III, Ludwig-Maximilians-University (LMU) University Hospital Munich, 81377 Munich, Germany.
Zitieren
APA
Haebe, S., Fraccaroli, A., Stauffer, E., Prevalsek, D., Zoellner, A. K., Drolle, H., Stemmler, H. J., Dreyling, M., von Bergwelt-Baildon, M., & Tischer, J. (2023). PTCY-Based Haploidentical Donor Transplantation versus HLA-Matched Related and Unrelated Donor Transplantations in Patients with Refractory or Relapsed Lymphoma—A Matched-Pair Analysis. Cancers, 15(21), 5246. https://doi.org/10.3390/cancers15215246
Vancouver
Haebe S, Fraccaroli A, Stauffer E, Prevalsek D, Zoellner AK, Drolle H, et al. PTCY-Based Haploidentical Donor Transplantation versus HLA-Matched Related and Unrelated Donor Transplantations in Patients with Refractory or Relapsed Lymphoma—A Matched-Pair Analysis. Cancers. 2023;15(21):5246. doi:10.3390/cancers15215246
BibTeX
@article{Haebe2023,
author = {Haebe, Sarah and Fraccaroli, Alessia and Stauffer, Elena and Prevalsek, Dusan and Zoellner, Anna K and Drolle, Heidrun and Stemmler, Hans-Joachim and Dreyling, Martin and von Bergwelt-Baildon, Michael and Tischer, Johanna},
title = {PTCY-Based Haploidentical Donor Transplantation versus HLA-Matched Related and Unrelated Donor Transplantations in Patients with Refractory or Relapsed Lymphoma—A Matched-Pair Analysis},
journal = {Cancers},
year = {2023},
volume = {15},
number = {21},
pages = {5246},
doi = {10.3390/cancers15215246}
}
EUVIMED